Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
BACKGROUND: Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a ch...
المؤلفون الرئيسيون: | Maini, R, St Clair, E, Breedveld, F, Furst, D, Kalden, J, Weisman, M, Smolen, J, Emery, P, Harriman, G, Feldmann, M, Lipsky, P |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
1999
|
مواد مشابهة
-
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
حسب: Lipsky, P, وآخرون
منشور في: (2000) -
Infliximab and methotrexate in the treatment of rheumatoid arthritis
حسب: Lipsky, P, وآخرون
منشور في: (2000) -
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
حسب: Elliott, M, وآخرون
منشور في: (1994) -
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
حسب: Maini, R, وآخرون
منشور في: (1998) -
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).
حسب: Furst, D, وآخرون
منشور في: (2000)